Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization

Inclusion criteria

• Significant unilateral or bilateral corneal neovascularization that extending over the limbus at least 2mm
• The underlying etiologies that caused corneal neovascularization included post penetrating keratoplasty (PKP), trauma, infectious or non-infectious corneal ulcer, post-keratoplasty, etc.
• Corneal neovascularization induced lipid keratopathy, corneal edema, or irregular corneal surface. The best-corrected visual acuity was less than 20/25
• Post-PKP corneal neovascularization that had no associated lipid keratopathy, no corneal edema, or corneal irregularity. But the neovascularization was highly possible to cause graft rejection.
• The corneal neovascularization was refractory to other medical treatment
• The patient had received PKP or other corneal surgeries more than half a year ago and was not in the acute post-operation phase
• The patient had no active endopthalmitis, glaucoma with uncontrolled intraocular pressure, or vitreoretinal diseases
• The patient signed inform consent to have regular follow up and treatment

Exclusion criteria

• The neovascularization had clinical improvement three months before the first injection
• The lipid keratopathy had clinical improvement three months before the first injection
• The patient that suspected to have poor visual outcome or had already been light sense negative
• Glaucoma patient that had uncontrolled intraocular pressure
• Poor corneal epithelialization
• Post-PKP patient that had graft failure or rejection
• Patient that had systemic disease which was not suitable for bevacizumab use
• Pregnant patient